12/22
10:25 am
ovid
Ovid Therapeutics (NASDAQ:OVID) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $4.00 price target on the stock.
Low
Report
Ovid Therapeutics (NASDAQ:OVID) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $4.00 price target on the stock.
12/22
08:02 am
ovid
Ovid Therapeutics (NASDAQ:OVID) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
High
Report
Ovid Therapeutics (NASDAQ:OVID) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
12/18
09:05 am
ovid
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV) [Yahoo! Finance]
Low
Report
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV) [Yahoo! Finance]
12/18
08:00 am
ovid
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
High
Report
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
12/12
05:52 am
ovid
Ovid Therapeutics (NASDAQ:OVID) was upgraded by analysts at Roth Capital to a "strong-buy" rating.
Low
Report
Ovid Therapeutics (NASDAQ:OVID) was upgraded by analysts at Roth Capital to a "strong-buy" rating.
12/11
06:03 am
ovid
Ovid Therapeutics (NASDAQ:OVID) is now covered by analysts at Roth Capital. They set a "buy" rating on the stock.
Low
Report
Ovid Therapeutics (NASDAQ:OVID) is now covered by analysts at Roth Capital. They set a "buy" rating on the stock.
12/2
07:00 am
ovid
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
High
Report
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
11/24
07:19 am
ovid
Ovid Therapeutics (NASDAQ:OVID) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Ovid Therapeutics (NASDAQ:OVID) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/18
07:21 am
ovid
Ovid Therapeutics (NASDAQ:OVID) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Medium
Report
Ovid Therapeutics (NASDAQ:OVID) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
11/17
08:06 am
ovid
Ovid Therapeutics (NASDAQ:OVID) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $5.00 price target on the stock.
Low
Report
Ovid Therapeutics (NASDAQ:OVID) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $5.00 price target on the stock.
11/12
09:26 am
ovid
Ovid Therapeutics (OVID) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
Medium
Report
Ovid Therapeutics (OVID) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
11/12
08:19 am
ovid
Ovid Therapeutics GAAP EPS of -$0.17 misses by $0.02, revenue of $0.13M misses by $0.04M [Seeking Alpha]
Low
Report
Ovid Therapeutics GAAP EPS of -$0.17 misses by $0.02, revenue of $0.13M misses by $0.04M [Seeking Alpha]
11/12
07:00 am
ovid
Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
Low
Report
Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
11/10
08:16 am
ovid
QurAlis Announces Appointment of Manoj Malhotra, M.D., as Chief Medical Officer [Yahoo! Finance]
Medium
Report
QurAlis Announces Appointment of Manoj Malhotra, M.D., as Chief Medical Officer [Yahoo! Finance]
10/26
06:18 am
ovid
B. Riley Lifts Ovid Therapeutics (OVID) PT to $5 on Strong OV329 Phase 1 Data [Yahoo! Finance]
Low
Report
B. Riley Lifts Ovid Therapeutics (OVID) PT to $5 on Strong OV329 Phase 1 Data [Yahoo! Finance]
10/10
12:04 pm
ovid
Ovid Therapeutics (NASDAQ:OVID) had its "buy" rating reaffirmed by analysts at B. Riley.
Low
Report
Ovid Therapeutics (NASDAQ:OVID) had its "buy" rating reaffirmed by analysts at B. Riley.
10/9
08:44 am
ovid
Ovid Therapeutics (NASDAQ:OVID) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $7.00 price target on the stock.
Medium
Report
Ovid Therapeutics (NASDAQ:OVID) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $7.00 price target on the stock.
10/6
01:50 pm
ovid
Ovid Therapeutics (OVID) Is Up 42.98% in One Week: What You Should Know [Yahoo! Finance]
Low
Report
Ovid Therapeutics (OVID) Is Up 42.98% in One Week: What You Should Know [Yahoo! Finance]
10/5
05:18 am
ovid
Ovid Therapeutics (OVID): Assessing Valuation Following Encouraging OV329 Phase 1 Trial Results [Yahoo! Finance]
Low
Report
Ovid Therapeutics (OVID): Assessing Valuation Following Encouraging OV329 Phase 1 Trial Results [Yahoo! Finance]
10/3
03:26 pm
ovid
Ovid Therapeutics: OV329 Promising For Neuronal Excitability In Neurological Disorders [Seeking Alpha]
Low
Report
Ovid Therapeutics: OV329 Promising For Neuronal Excitability In Neurological Disorders [Seeking Alpha]
10/3
01:03 pm
ovid
Ovid Therapeutics Inc. (OVID) OV329 Topline Results Webcast from the Phase 1 Healthy Volunteer Study Transcript [Seeking Alpha]
Medium
Report
Ovid Therapeutics Inc. (OVID) OV329 Topline Results Webcast from the Phase 1 Healthy Volunteer Study Transcript [Seeking Alpha]
10/3
12:54 pm
ovid
Ovid Therapeutics Inc. - Special Call [Seeking Alpha]
Medium
Report
Ovid Therapeutics Inc. - Special Call [Seeking Alpha]
10/3
07:59 am
ovid
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds [Yahoo! Finance]
Medium
Report
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds [Yahoo! Finance]
10/3
07:23 am
ovid
Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile [Yahoo! Finance]
Medium
Report
Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile [Yahoo! Finance]
10/3
07:05 am
ovid
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
High
Report
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds